Max Portfolio Pct.
Check
Valuation
Check
Stock Quality:
Max Portfolio Pct.
Check
Valuation
Check
AMGN Price Action
Last 7 days
0.1%
Last 30 days
-8%
Last 90 days
-1.5%
Trailing 12 Months
1.0%
AMGN RSI Chart
AMGN Valuation
AMGN Price/Sales (Trailing)
The Good, Bad and Ugly
Growth
Profitability
Size
Dilution Risk
Balance Sheet
Momentum
Funds Popularity
Insider Trading
AMGN Fundamentals
AMGN Revenue
AMGN Earnings
AMGN Profitability
AMGN Investor Care
AMGN Alerts
The Good News
Analysts have given Amgen (AMGN) a Moderate Buy rating, with notable price targets set at $329.00 by Piper Sandler and $350.00 by Jefferies, indicating potential upside for investors (Sources: Markets Insider https://markets.businessinsider.com/news/stocks/amgen-amgn-receives-a-buy-from-jefferies-1034581426). Expectations for earnings growth with $4.15 EPS and $7.94 billion in revenue for the upcoming earnings report also reflect optimism about the company’s future performance (Sources: Yahoo Finance).
The Bad News
Amgen (AMGN) has experienced a 12.26% decline in stock value over the past month, closing at $273.68 (Sources: Yahoo Finance). The recent quarterly earnings show a drop in revenue to $9.09 billion and net profit to $627 million compared to the previous year, raising concerns among analysts (Sources: Markets Insider). Furthermore, an increase in insider selling activity indicates negative sentiment within the company (Sources: Markets Insider).
Revenue & Growth
Revenue Breakdown
As of: Dec 31, 2024
Other Products
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2025 | 34.1B | 0 | 0 | 0 |
| 2024 | 29.5B | 30.9B | 32.5B | 33.4B |
| 2023 | 26.2B | 26.6B | 26.8B | 28.2B |
| 2022 | 26.3B | 26.4B | 26.3B | 26.3B |
| 2021 | 25.2B | 25.5B | 25.8B | 26.0B |
| 2020 | 24.0B | 24.3B | 25.0B | 25.4B |
| 2019 | 23.8B | 23.6B | 23.4B | 23.4B |
| 2018 | 22.9B | 23.2B | 23.3B | 23.7B |
| 2017 | 22.9B | 23.1B | 23.0B | 22.8B |
| 2016 | 22.2B | 22.5B | 22.6B | 23.0B |
| 2015 | 20.6B | 20.8B | 21.5B | 21.7B |
| 2014 | 19.0B | 19.5B | 19.7B | 20.1B |
| 2013 | 17.5B | 17.7B | 18.1B | 18.7B |
| 2012 | 15.9B | 16.4B | 16.8B | 17.3B |
| 2011 | 15.2B | 15.3B | 15.4B | 15.6B |
| 2010 | 14.9B | 15.0B | 15.0B | 15.1B |
| 2009 | 14.7B | 14.6B | 14.6B | 14.6B |
| 2008 | 0 | 14.8B | 14.9B | 15.0B |
| 2007 | 0 | 0 | 0 | 14.8B |
Get all data in R, Python etc through our Historical Stock Data APIs
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
| CEO | Mr. Robert A. Bradway |
|---|---|
| WEBSITE | amgen.com |
| SECTOR | Healthcare |
| INDUSTRY | Drug Manufacturers General |
| EMPLOYEES | 25200 |
